SCHEMBL309368

SCHEMBL309368

CCn1cnc2c(OC)cc(C(=O)OC)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 4/20 0.40
CYP3A4 P08684 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
YTHDC1 Q96MU7 2/20 0.39
TSHR P16473 1/20 0.39
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219842 0.85 KDM4E (0.40) KDM4EALDH1A1SMN1; SMN2MAPTYTHDC1
SCHEMBL5218276 0.81 KDM4E (0.52) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL31009266 0.80 ALDH1A1 (0.42) KDM4EALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL31009254 0.80 ALDH1A1 (0.42) KDM4EALDH1A1SMN1; SMN2TSHRMEN1
SCHEMBL22777930 0.80 HDAC6 (0.43) KDM4EALDH1A1SMN1; SMN2TP53MAPT
SCHEMBL29633692 0.78 CREBBP (0.41) KDM4EALDH1A1SMN1; SMN2MAPTCYP3A4
SCHEMBL28715350 0.78 CREBBP (0.41) KDM4EALDH1A1SMN1; SMN2MAPTCYP3A4
SCHEMBL5218022 0.76 BACE1 (0.50) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C9
SCHEMBL17263019 0.76 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2MAPTHSD17B10
SCHEMBL5219791 0.75 CTSD (0.36) KDM4EALDH1A1SMN1; SMN2MAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2111406-B1 SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS MERCK SHARP & DOHME (US) 2012-10-24 EP disclosed
US-8093389-B2 e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases MERCK SHARP & DOHME CORP. (US) 2012-01-10 US disclosed
US-20080171761-A1 Substituted spirochromanone derivatives MERCK SHARP & DOHME LLC 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171761-A1 Substituted spirochromanone derivatives CBR3, CBR1, CNKSR1 KDM4E 4093/4885ALDH1A1 901/4885SMN1; SMN2 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.